

# Measuring Pharmaceutical Quality through Manufacturing Metrics and Risk-Based Assessment

The Brookings Institution • Washington, DC May 1 & 2, 2014

May 1<sup>st</sup>, 2014

8:30 a.m. Welcome and Overview

Mark McClellan, Health Care Innovation and Value Initiative, Brookings Institution Greg Daniel, Engelberg Center for Health Care Reform, Brookings Institution

8:45 a.m. Office of Pharmaceutical Quality (OPQ): An Evolution Towards Quality in Review,

Inspection, and Surveillance

Theresa Mullin, U.S. Food and Drug Administration

9:00 a.m. Pharmaceutical Quality Metrics: Goals and Stakeholder Feedback

Mark McClellan — *Moderator* 

Russell Wesdyk, U.S. Food and Drug Administration

Katy George, McKinsey & Company

10:15 a.m. Break

10:30 a.m. Reflecting on the Consensus Set of Metrics and Approaches

Mark McClellan — *Moderator* G.K. Raju, Light Pharma Inc. Martin VanTrieste, Amgen, Inc.

Donna Gulbinski, Bristol-Myers Squibb

Vinay Bhatt, Zydus Pharmaceuticals (USA) LLC

11:30 a.m. Exploring the Use of Metrics in Purchasing Decisions

Mark McClellan — Moderator

Paula Gurz, Premier Healthcare Alliance

Ferdinando Aspesi, Novartis Deborah M. Autor, Mylan

12:30 p.m. Lunch

#### 1:30 p.m. Opportunities and Challenges in Implementing a Core Set of Metrics

Mark McClellan — *Moderator*Barbara Allen, Eli Lilly and Company

Linda Evans O'Connor, Teva Pharmaceuticals

Joachim Del Boca, Vetter Pharma-Fertigung GmbH & Co. KG

Luisa Paulo, Hovione FarmaCiencia SA

### 3:30 p.m. Presentation of Metrics Discussion Set

Mark McClellan — *Moderator* 

Russell Wesdyk, U.S. Food and Drug Administration

## 4:50 p.m. Closing Remarks

**Greg Daniel** 

### 5:00 p.m. Adjournment



# Measuring Pharmaceutical Quality through Manufacturing Metrics and Risk-Based Assessment

The Brookings Institution • Washington, DC May 1 & 2, 2014

# May 2<sup>nd</sup>, 2014

4:00 p.m.

**Adjournment** 

8:30 a.m.	Welcome and Overview Greg Daniel, Engelberg Center for Health Care Reform, Brookings Institution
8:45 a.m.	U.S. Food and Drug Administration Remarks Theresa Mullin, U.S. Food and Drug Administration
9:00 a.m.	Review of Metrics Discussion Set  Greg Daniel — Moderator  Russell Wesdyk, U.S. Food and Drug Administration
9:15 a.m.	Exploring and Adapting the Metrics Discussion Set: Concerns, Additions, and Deletions Greg Daniel — $Moderator$
10:45 a.m.	Break
11:00 a.m.	Exploring and Adapting the Metrics Discussion Set: Definitions  Greg Daniel — <i>Moderator</i>
12:00 p.m.	Lunch
1:00 p.m.	Exploring and Adapting the Metrics Discussion Set: Issues in Implementation Greg Daniel — <i>Moderator</i>
2:30 p.m.	Break
2:45 p.m.	Next Steps in Metrics Discussion Set  Greg Daniel – Moderator
3:50 p.m.	Closing Remarks Greg Daniel

Convened by the Engelberg Center for Health Care Reform at Brookings and supported by a cooperative agreement with the U.S. Food and Drug Administration